tigenix.com
. TiGenix NV is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
Listed on Euronext
(Belgium): TIG
Exited
. TiGenix NV is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.
Listed on Euronext
(Belgium): TIG
Exited
Location: Belgium, Flemish Brabant, Leuven
Employees: 51-200
Total raised: $15.07M
Founded date: 2000
Investors 2
| Date | Name | Website |
| - | Auriga Par... | auriga.vc |
| - | KU Leuven ... | lrd.kuleuv... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 27.12.2011 | Grant | $3.79M | - |
| 14.12.2009 | - | $11.28M | - |
Mentions in press and media 16
| Date | Title | Description |
| 24.03.2018 | TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval | TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601, for the t... |
| 05.01.2018 | Takeda announces its intention to acquire TiGenix | TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel ther... |
| 15.12.2016 | TiGenix, participada por Ysios, obtiene $35,65M con la oferta pública en el Nasdaq | 15/12/2016 TIGENIX, PARTICIPADA POR YSIOS, OBTIENE $35,65 MILLONES CON LA OFERTA PÚBLICA EN EL NASDAQ. TiGenix NV (Euronext Brussels: TIG; "TiGenix"), empresa biofarmacéutica participada por la entidad de capital riesgo (venture... |
| 07.12.2016 | Tigenix, participada por Ysios Capital, anuncia su salto al Nasdaq | 07/12/2016 TIGENIX, PARTICIPADA POR YSIOS CAPITAL, ANUNCIA SU SALTO AL NASDAQ. TiGenix NV, participada por la entidad de capital riesgo (venture capital) Ysios Capital, ha anunciado hoy su intención de ofrecer y vender, sujeto a las condi... |
| 06.12.2016 | TiGenix files for $43M IPO to fund stem cell therapy phase 3 | TiGenix has taken another step toward its delayed Nasdaq IPO. The stem cell therapy specialist is aiming to net $42.9 million (€39.8 million) through the listing, approximately half of which will go toward a U.S. late-phase trial of Crohn's... |
| 09.01.2012 | TiGenix reports positive results of ChondroCelect® compassionate use program | TiGenix reports positive results of ChondroCelect® compassionate use program 09-01-2012 TiGenix, a leading biopharmaceutical company that commercialises and develops cell therapies, today announced data from a ChondroCelect® compassionate u... |
| 27.12.2011 | TiGenix obtains EUR 2.9 million FP7 grant to fund development of Cx611 in rheumatoid arthr... | TiGenix obtains EUR 2.9 million FP7 grant to fund development of Cx611 in rheumatoid arthr... 27-12-2011 TiGenix, a leading biopharmaceutical company that commercialises and develops cell therapies, announced that as the coordinator of an i... |
| 23.12.2011 | TiGenix obtiene una subvención de €2,9 millones del Séptimo Programa Marco | 23/12/2011 Nota de Prensa TIGENIX OBTIENE UNA SUBVENCIÓN DE €2,9 MILLONES DEL SÉPTIMO PROGRAMA MARCO. TiGenix, compañía biofarmacéutica líder que comercializa y desarrolla terapias celulares, ha anunciado que, como coordinador de un cons... |
| 21.12.2011 | TiGenix receives green light to start Phase I with Cx621 | TiGenix receives green light to start Phase I with Cx621 21-12-2011 TiGenix (NYSE Euronext: TIG) announced that it has obtained all the required approvals to start the company's Phase I clinical trial to assess the safety of intra-lymphatic... |
| 10.11.2010 | TiGenix completes second phase of the Orthomimetics acquisition | TiGenix completes second phase of the Orthomimetics acquisition 10-11-2010 TiGenix announces that it has completed the second phase of the acquisition of Cambridge medical technology company Orthomimetics. TiGenix has performed a capital in... |
Show more